>>> Pfizer beats by $0.01, misses on revs; raises low end of FY17 EPS, reaffirms

Pfizer beats by $0.01, misses on revs; raises low end of FY17 EPS, reaffirms FY17 revs guidance (33.16)
  • Reports Q2 (Jun) earnings of $0.67 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.66; revenues fell 1.9% year/year to $12.9 bln vs the $13.08 bln Capital IQ Consensus. reflecting a slight operational decline of $48 million and the unfavorable impact of foreign exchange of $202 million, or 2%. Excluding the revenues for HIS in both periods and the unfavorable impact of foreign exchange, second-quarter 2017 revenues increased by $248 million, or 2%. Second-quarter 2017 revenues excluding the net impact of acquisitions and divestitures completed in 2016 and the first six months of 2017 were flat operationally compared to second-quarter 2016.
  • Co issues guidance for FY17, raises EPS to $2.54-2.60 from $2.50-2.60, excluding non-recurring items, vs. $2.55 Capital IQ Consensus Estimate; reaffirms FY17 revs of $52-54 bln vs. $52.78 bln Capital IQ Consensus Estimate.